Exacis Biotherapeutics Inc. — Form D
Exacis Biotherapeutics Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2021-02-03. The offering totals $3.0M, of which $1.1M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2021-02-03
- Form: D
- Accession: 0001844030-21-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $3.0M
- Amount sold: $1.1M
- Remaining: $1.9M
- Minimum investment: $25K
- Investors: 14
- Date of first sale: 2020-10-21
- Revenue range: Decline to Disclose
- SEC file number: 021-388357
Issuer
- Name: Exacis Biotherapeutics Inc.
- CIK: 0001844030
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2020
- Address: 1035 CAMBRIDGE STREET, CAMBRIDGE, MA, 02141
- Phone: 1 917 415 3000
Officers, directors & promoters (3)
| Name | Role | Location |
|---|
| Matthew Angel | Director | Brisbane, CA |
| Gregory Fiore | Executive Officer | Cambridge, MA |
| Mark Corrigan | Director | Cambridge, MA |
Other filings by this issuer (1)
More